8-K Announcements
6Material company update
Apr 13, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Feb 19, 2026·SEC
Spyre Therapeutics, Inc.(SYRE)Earnings, Financials & Key Ratios
SYRE•NASDAQ
$70.94
$4.27B mkt cap·Price updated May 6, 2026
AboutSpyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$208M+13.8%
- Net Income-$208M+38.6%
- EPS (Diluted)-3.18+93.1%
- ROE-59.28%+79.5%
- ROIC-73.87%+96.9%
SYRE Key Insights
Spyre Therapeutics, Inc. (SYRE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SYRE Price & Volume
Spyre Therapeutics, Inc. (SYRE) stock price & volume — 10-year historical chart
Loading chart...
SYRE Growth Metrics
Spyre Therapeutics, Inc. (SYRE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM30.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM83.73%
Return on Capital
10 Years-78.09%
5 Years-85.99%
3 Years-98.82%
Last Year-48.26%
SYRE Recent Earnings
Spyre Therapeutics, Inc. (SYRE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (75%)
Q1 2026Latest
Feb 19, 2026EPS
$0.70
Est $0.66
-6.1%
Revenue
$90M
Est $143M
-36.7%
Q4 2025
Nov 4, 2025EPS
$0.15
Est $0.68
+77.9%
Revenue
—
Q3 2025
Aug 5, 2025EPS
$0.49
Est $0.73
+32.9%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.74
Est $0.76
+2.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 19, 2026 | $0.70vs $0.66-6.1% | $90Mvs $143M-36.7% |
| Q4 2025 | Nov 4, 2025 | $0.15vs $0.68+77.9% | — |
| Q3 2025 | Aug 5, 2025 | $0.49vs $0.73+32.9% | — |
| Q2 2025 | May 8, 2025 | $0.74vs $0.76+2.6% | — |
Based on last 12 quarters of dataView full earnings history →
SYRE Peer Comparison
Spyre Therapeutics, Inc. (SYRE) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARRY | 1.25B | 8.18 | -11.21 | 40.22% | -4.07% | -20.06% | 0.41 | |
 PRTA | 602.39M | 11.19 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 TRMB | 16.27B | 68.37 | 39.07 | -2.61% | 11.82% | 7.27% | 0.82% | 0.24 |
 PTGX | 6.21B | 99.28 | -48.43 | -100% | -21.17% | 0.93% | 0.02 | |
 TERN | 4.64B | 52.97 | -47.29 | -29.95% | 0.00 | |||
 JANX | 865.31M | 14.33 | -7.83 | -5.55% | -8.82% | -16.48% | 0.02 | |
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% | |
 JNJ | 543.64B | 225.59 | 38.96 | 4.3% | 27.26% | 31.69% | 3.65% | 0.51 |
Compare SYRE vs Peers
Spyre Therapeutics, Inc. (SYRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SYRE Income Statement
Spyre Therapeutics, Inc. (SYRE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.63M | 5.21M | 3.89M | 0 | 0 | 18.74M | 2.33M | 886K | 0 | 0 |
| Revenue Growth % | -23.94% | 12.47% | -25.3% | -100% | - | - | -87.57% | -61.96% | -100% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 901K | 1.62M | 0 | 0 | 0 | 0 | 45.25M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -901K▲ 0% | -1.62M▼ 80.2% | 18.74M▲ 1253.9% | 2.33M▼ 87.6% | 886K▼ 62.0% | 0▼ 100.0% | -45.25M▲ 0% |
| Gross Margin % | - | - | - | - | - | 100% | 100% | 100% | - | - |
| Gross Profit Growth % | - | - | - | - | -80.24% | 1253.88% | -87.57% | -61.96% | -100% | - |
| Operating Expenses | 26.53M | 32.88M | 49.35M | 79.43M | 79.86M | 84.39M | 87.11M | 243.19M | 208.57M | 168.4M |
| OpEx % of Revenue | 573.34% | 631.72% | 1269.32% | - | - | 450.33% | 3740.23% | 27447.97% | - | - |
| Selling, General & Admin | 8.39M | 10.07M | 12.63M | 14.83M | 20.22M | 27.32M | 28.53M | 39.95M | 45.78M | 46.15M |
| SG&A % of Revenue | 181.31% | 193.39% | 324.9% | - | - | 145.79% | 1225.03% | 4508.58% | - | - |
| Research & Development | 18.14M | 22.82M | 36.72M | 64.6M | 59.64M | 57.07M | 58.58M | 89.5M | 162.79M | 177.5M |
| R&D % of Revenue | 392.03% | 438.33% | 944.42% | - | - | 304.55% | 2515.2% | 10102.03% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 113.74M | 0 | -2M |
| Operating Income | -21.91M▲ 0% | -27.68M▼ 26.3% | -45.46M▼ 64.3% | -80.33M▼ 76.7% | -81.48M▼ 1.4% | -65.65M▲ 19.4% | -84.78M▼ 29.1% | -242.3M▼ 185.8% | -208.57M▲ 13.9% | -213.64M▲ 0% |
| Operating Margin % | -473.34% | -531.72% | -1169.32% | - | - | -350.33% | -3640.23% | -27347.97% | - | - |
| Operating Income Growth % | -93.6% | -26.34% | -64.27% | -76.7% | -1.43% | 19.43% | -29.14% | -185.8% | 13.92% | - |
| EBITDA | -21.77M | -27.43M | -45.17M | -79.43M | -79.86M | -64.07M | -82.82M | -241.34M | -207.97M | -177.94M |
| EBITDA Margin % | -470.48% | -526.94% | -1161.78% | - | - | -341.92% | -3555.9% | -27239.16% | - | - |
| EBITDA Growth % | -93.96% | -25.96% | -64.69% | -75.85% | -0.53% | 19.77% | -29.25% | -191.41% | 13.83% | 8.02% |
| D&A (Non-Cash Add-back) | 132K | 249K | 293K | 901K | 1.62M | 1.58M | 1.96M | 964K | 0 | 0 |
| EBIT | -21.91M | -27.68M | -45.46M | -78.25M | -80.89M | -65.65M | -84.78M | -128.56M | -207.97M | -177.94M |
| Net Interest Income | 244K | 482K | 1.17M | 2.14M | 593K | 111K | 837K | 6.15M | 21.31M | 23.52M |
| Interest Income | 244K | 482K | 1.17M | 2.14M | 593K | 111K | 837K | 6.15M | 21.31M | 23.52M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 208K | 440K | 1.11M | 2.08M | 588K | -11K | 830K | -96.51M | 599K | 64.66M |
| Pretax Income | -21.7M▲ 0% | -27.24M▼ 25.5% | -44.35M▼ 62.8% | -78.25M▼ 76.5% | -80.89M▼ 3.4% | -65.66M▲ 18.8% | -83.95M▼ 27.9% | -338.82M▼ 303.6% | -207.97M▲ 38.6% | -148.98M▲ 0% |
| Pretax Margin % | -468.84% | -523.27% | -1140.64% | - | - | -350.39% | -3604.59% | -38241.08% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 141K | -136K | -26K | 51K | -14K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | -0.21% | 0.16% | 0.01% | -0.02% | 0.01% |
| Net Income | -21.7M▲ 0% | -27.24M▼ 25.5% | -44.35M▼ 62.8% | -78.25M▼ 76.5% | -80.89M▼ 3.4% | -65.8M▲ 18.7% | -83.81M▼ 27.4% | -338.79M▼ 304.2% | -208.02M▲ 38.6% | -148.97M▲ 0% |
| Net Margin % | -468.84% | -523.27% | -1140.64% | - | - | -351.14% | -3598.75% | -38238.15% | - | - |
| Net Income Growth % | -92.1% | -25.52% | -62.83% | -76.45% | -3.37% | 18.66% | -27.38% | -304.21% | 38.6% | 30.68% |
| Net Income (Continuing) | -21.7M | -27.24M | -44.35M | -78.25M | -80.89M | -65.8M | -83.81M | -338.79M | -208.02M | -148.97M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -55.40▲ 0% | -45.01▲ 18.8% | -53.25▼ 18.3% | -61.23▼ 15.0% | -37.89▲ 38.1% | -25.02▲ 34.0% | -24.86▲ 0.6% | -46.15▼ 85.6% | -3.18▲ 93.1% | -2.47▲ 0% |
| EPS Growth % | -124.2% | 18.75% | -18.31% | -14.99% | 38.12% | 33.97% | 0.64% | -85.64% | 93.11% | 83.73% |
| EPS (Basic) | -55.40 | -45.01 | -53.25 | -61.23 | -37.89 | -25.02 | -24.86 | -46.15 | -3.18 | - |
| Diluted Shares Outstanding | 391.67K | 605.13K | 832.9K | 1.28M | 2.13M | 2.63M | 3.37M | 6.9M | 47.03M | 60.41M |
| Basic Shares Outstanding | 391.67K | 605.13K | 832.9K | 1.28M | 2.13M | 2.63M | 3.37M | 6.9M | 47.03M | 74.93M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SYRE Balance Sheet
Spyre Therapeutics, Inc. (SYRE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 66.42M | 54.99M | 76.67M | 74.5M | 149.79M | 98.89M | 62.26M | 341.53M | 608.47M | 504.6M |
| Cash & Short-Term Investments | 63.5M | 50.3M | 74.51M | 71.95M | 146.27M | 93.13M | 55.71M | 339.28M | 603.09M | 486.2M |
| Cash Only | 47.75M | 12.82M | 22.46M | 19.25M | 90.09M | 15.14M | 34.86M | 188.89M | 89.42M | 64.9M |
| Short-Term Investments | 15.75M | 37.48M | 52.05M | 52.7M | 56.18M | 77.99M | 20.85M | 150.38M | 513.66M | 421.3M |
| Accounts Receivable | 1.22M | 3.08M | 0 | 0 | 0 | 815K | 375K | 0 | 0 | 0 |
| Days Sales Outstanding | 95.82 | 215.84 | - | - | - | 15.87 | 58.77 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 6.17M | 2.25M | 5.39M | 18.41M |
| Total Non-Current Assets | 639K | 1.09M | 1.07M | 8.68M | 11.83M | 11.04M | 8.89M | 331K | 10K | 0 |
| Property, Plant & Equipment | 599K | 854K | 1.02M | 7.11M | 9.87M | 8.36M | 6.65M | 0 | 0 | 0 |
| Fixed Asset Turnover | 7.73x | 6.09x | 3.82x | - | - | 2.24x | 0.35x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 40K | 232K | 50K | 1.57M | 1.96M | 2.68M | 2.24M | 331K | 10K | 20K |
| Total Assets | 67.06M▲ 0% | 56.08M▼ 16.4% | 77.74M▲ 38.6% | 83.18M▲ 7.0% | 161.62M▲ 94.3% | 109.93M▼ 32.0% | 71.14M▼ 35.3% | 341.86M▲ 380.5% | 608.48M▲ 78.0% | 504.6M▲ 0% |
| Asset Turnover | 0.07x | 0.09x | 0.05x | - | - | 0.17x | 0.03x | 0.00x | - | 0.00x |
| Asset Growth % | 73.5% | -16.38% | 38.63% | 7% | 94.29% | -31.98% | -35.28% | 380.52% | 77.99% | 138.25% |
| Total Current Liabilities | 3.96M | 5.63M | 10.24M | 18.36M | 16.44M | 20.14M | 14.66M | 31.98M | 54.06M | 46.27M |
| Accounts Payable | 168K | 389K | 663K | 3.15M | 2.25M | 3.32M | 677K | 896K | 666K | 7.46M |
| Days Payables Outstanding | - | - | - | 1.28K | 506.59 | - | - | - | - | 31.31 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 71K | 20K | 0 | 0 | 0 | 2.36M | 517K | 0 | 0 | 0 |
| Other Current Liabilities | 1.5M | 3.38M | 2.78M | 3.74M | 4.18M | 4.99M | 4.92M | 5.93M | 52.79M | 16.32M |
| Current Ratio | 16.75x | 9.77x | 7.49x | 4.06x | 9.11x | 4.91x | 4.25x | 10.68x | 11.26x | 11.26x |
| Quick Ratio | 16.75x | 9.77x | 7.49x | 4.06x | 9.11x | 4.91x | 4.25x | 10.68x | 11.26x | 11.26x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 132K | 111K | 72K | 4.74M | 5.34M | 5.84M | 6.18M | 125.86M | 36.62M | 3.23M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 4.71M | 5.13M | 4.62M | 4M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 132K | 111K | 72K | 31K | 214K | 0 | 0 | 125.86M | 36.62M | 56.34M |
| Total Liabilities | 4.1M | 5.74M | 10.31M | 23.1M | 21.79M | 25.98M | 20.84M | 157.84M | 90.68M | 49.5M |
| Total Debt | 0 | 0 | 0 | 5.06M | 5.45M | 5.06M | 4.63M | 0 | 0 | 0 |
| Net Debt | -47.75M | -12.82M | -22.46M | -14.19M | -84.65M | -10.08M | -30.23M | -188.89M | -89.42M | -64.9M |
| Debt / Equity | - | - | - | 0.08x | 0.04x | 0.06x | 0.09x | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.36x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 62.97M▲ 0% | 50.34M▼ 20.1% | 67.43M▲ 34.0% | 60.08M▼ 10.9% | 139.83M▲ 132.7% | 83.94M▼ 40.0% | 50.3M▼ 40.1% | 184.02M▲ 265.8% | 517.8M▲ 181.4% | 455.1M▲ 0% |
| Equity Growth % | 74.4% | -20.06% | 33.95% | -10.9% | 132.74% | -39.97% | -40.07% | 265.8% | 181.39% | 459.08% |
| Book Value per Share | 160.76 | 83.18 | 80.96 | 47.01 | 65.50 | 31.92 | 14.92 | 26.68 | 11.01 | 7.53 |
| Total Shareholders' Equity | 62.97M | 50.34M | 67.43M | 60.08M | 139.83M | 83.94M | 50.3M | 184.02M | 517.8M | 455.1M |
| Common Stock | 1K | 2K | 2K | 3K | 5K | 5K | 6K | 10K | 13K | 13K |
| Retained Earnings | -45.28M | -72.51M | -116.86M | -195.12M | -276.01M | -341.81M | -425.62M | -764.41M | -972.43M | -1.07B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4K | -102K | -27K | 51K | 11K | -20K | -48K | 302K | 180K | 791K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SYRE Cash Flow Statement
Spyre Therapeutics, Inc. (SYRE) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.84M | -24.61M | -32.19M | -65.69M | -75.78M | -53.72M | -80.14M | -99.91M | -157.41M | -157.41M |
| Operating CF Margin % | -407.09% | -472.91% | -828.01% | - | - | -286.65% | -3441.13% | -11276.52% | - | - |
| Operating CF Growth % | -71.55% | -30.65% | -30.79% | -104.06% | -15.35% | 29.11% | -49.2% | -24.66% | -57.55% | -64.45% |
| Net Income | -21.7M | -27.24M | -44.35M | -78.25M | -80.89M | -65.8M | -83.81M | -338.79M | -208.02M | -148.97M |
| Depreciation & Amortization | 132K | 249K | 293K | 901K | 996K | 1.58M | 1.57M | 744K | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 6.26M | 8.04M | 7.11M | 25.68M | 44.83M | 27.45M |
| Deferred Taxes | 0 | 0 | 0 | 0 | -213K | 0 | -327K | 0 | 0 | 0 |
| Other Non-Cash Items | 1.07M | 4.77M | 1.93M | 3.78M | 619K | 638K | 823K | 217.67M | 10.31M | -47.49M |
| Working Capital Changes | 1.45M | -198K | 7.2M | 7.1M | -2.54M | 1.83M | -5.5M | -5.21M | -4.53M | 7.13M |
| Change in Receivables | 482K | -1.86M | 3.08M | 0 | 0 | -815K | 440K | 375K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -440K | 0 | 0 | 0 |
| Change in Payables | -8K | 164K | 239K | 2.58M | -544K | 1.06M | -2.64M | 218K | -230K | -11.74M |
| Cash from Investing | -12.16M | -22.53M | -15.23M | -1.74M | -7.6M | -22.62M | 57.01M | -108.39M | -353.29M | -66.61M |
| Capital Expenditures | -212K | -619K | -422K | -1.49M | -4.28M | -573K | -38K | 0 | 0 | 0 |
| CapEx % of Revenue | 4.58% | 11.89% | 10.85% | - | - | 3.06% | 1.63% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.04M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.47M | 0 | 7M |
| Cash from Financing | 49.37M | 12.21M | 57.07M | 65.72M | 154.51M | 1.39M | 42.68M | 361.08M | 410.91M | 221.81M |
| Debt Issued (Net) | 0 | 0 | 0 | -25K | -20K | -510K | -418K | -16K | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 2.1M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -117K |
| Other Financing | 76K | 833K | 3.02M | 1.45M | 816K | 1.9M | 222K | -5.38M | 5.67M | -3.91M |
| Net Change in Cash | 18.37M▲ 0% | -34.93M▼ 290.1% | 9.64M▲ 127.6% | -3.21M▼ 133.3% | 71.18M▲ 2319.0% | -74.96M▼ 205.3% | 19.44M▲ 125.9% | 152.8M▲ 686.2% | -99.79M▼ 165.3% | -6.68M▲ 0% |
| Free Cash Flow | -19.05M▲ 0% | -25.23M▼ 32.4% | -32.62M▼ 29.3% | -67.18M▼ 106.0% | -80.06M▼ 19.2% | -54.29M▲ 32.2% | -80.18M▼ 47.7% | -99.91M▼ 24.6% | -157.41M▼ 57.6% | -161.87M▲ 0% |
| FCF Margin % | -411.67% | -484.8% | -838.86% | - | - | -289.71% | -3442.77% | -11276.52% | - | - |
| FCF Growth % | -70.26% | -32.45% | -29.25% | -105.99% | -19.16% | 32.19% | -47.69% | -24.6% | -57.55% | -7.03% |
| FCF per Share | -48.64 | -41.70 | -39.16 | -52.57 | -37.50 | -20.64 | -23.78 | -14.49 | -3.35 | -3.35 |
| FCF Conversion (FCF/Net Income) | 0.87x | 0.90x | 0.73x | 0.84x | 0.94x | 0.82x | 0.96x | 0.29x | 0.76x | 1.09x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SYRE Key Ratios
Spyre Therapeutics, Inc. (SYRE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -43.8% | -48.08% | -75.32% | -122.74% | -80.93% | -58.81% | -124.87% | -289.17% | -59.28% | -32.73% |
| Return on Invested Capital (ROIC) | -149.17% | -78.72% | -82.67% | -132.63% | -120.92% | -76.31% | -135.39% | -2392.09% | -73.87% | -73.87% |
| Gross Margin | - | - | - | - | - | 100% | 100% | 100% | - | - |
| Net Margin | -468.84% | -523.27% | -1140.64% | - | - | -351.14% | -3598.75% | -38238.15% | - | - |
| Debt / Equity | - | - | - | 0.08x | 0.04x | 0.06x | 0.09x | - | - | 0.00x |
| FCF Conversion | 0.87x | 0.90x | 0.73x | 0.84x | 0.94x | 0.82x | 0.96x | 0.29x | 0.76x | 1.09x |
| Revenue Growth | -23.94% | 12.47% | -25.3% | -100% | - | - | -87.57% | -61.96% | -100% | - |
SYRE SEC Filings & Documents
Spyre Therapeutics, Inc. (SYRE) SEC filings — annual & quarterly reports (10-K, 10-Q)
SYRE Frequently Asked Questions
Spyre Therapeutics, Inc. (SYRE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Spyre Therapeutics, Inc. (SYRE) saw revenue decline by 100.0% over the past year.
Spyre Therapeutics, Inc. (SYRE) reported a net loss of $149.0M for fiscal year 2024.
Dividend & Returns
Spyre Therapeutics, Inc. (SYRE) has a return on equity (ROE) of -59.3%. Negative ROE indicates the company is unprofitable.
Spyre Therapeutics, Inc. (SYRE) had negative free cash flow of $161.9M in fiscal year 2024, likely due to heavy capital investments.
Explore More SYRE
Spyre Therapeutics, Inc. (SYRE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates